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Estimating the type-specific prevalence of human papillomavirus (HPV) in head and neck cancer 
(HNSCC) is helpful in predicting the impact of HPV immunization.
Objective: To estimate the overall prevalence, and gender and age-specific prevalence of HPV in 
HNSCC.
Method: This cross sectional retrospective study was carried out in four pathology laboratories of 
Medellin, Colombia. HPV testing was performed by GP5+/6+ PCR-based RLB and HPV 16 and 18 
type-specific PCR.
Results: 175 primary HNSCC cases consecutively diagnosed between 1999 and 2008 with confirmed 
diagnosis and amplifiable DNA were included. Overall HPV prevalence was 18.9%. HPV was found 
in 23.9%, 17.5% and 13.3% of the oral cavity, larynx and oropharynx cases respectively. Among HPV 
positive cases, 82% were HPV 16 and 18% were HPV 18. No other HPV genotypes were identified. 
Most patients were males. Male patients were younger that their female counterparts, particularly 
in oral cavity cancer cases.
Conclusion: HPV 16 and 18 genotypes were found in nearly 20% of HNSCC cases in Colombian 
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INTRODUCTION
The head and neck squamous cell carcinoma 
(HNSCC) is the fifth most common cancer worldwide, 
with around 600.000 cases diagnosed in 20081. Most of 
these cancers arise from squamous cells in the oral cav-
ity, oropharynx, nasopharynx, hypopharynx and larynx. 
Smoking and alcohol drinking are known risk factors for 
these cancers2, and Epstein-Barr virus has been recognized 
as a cause of nasopharyngeal cancer3.
The relationship of Human Papillomavirus (HPV) 
with a subset of HNSCC cases has been firmly estab-
lished4-7. HPV positive HNSCC cases are associated with 
younger age, male predominance and risky sexual behav-
iors such as a high number of sexual partners and history 
of oral sex8-10. In contrast HPV-negative HNSCC is most 
likely related to cumulative measures of smoking and 
alcohol drinking and poor oral hygiene11. Cancers of the 
tonsils and base of the tongue are the sites more frequently 
associated with HPV but HPV has been also detected in 
oral cavity and larynx.
A systematic review that included 5,046 specimens 
of HNSCC of 60 studies that used PCR-based methods 
to detect the genotype of HPV12 showed and estimated 
prevalence of HPV DNA of about 25.9% of these tumors. 
The prevalence was significantly higher in cancer of 
the oropharynx (35.6%, range 11-100%) than in the oral 
cavity (23.5%, range 40% to 80%) or larynx (24.0%, range 
0-100%) with HPV 16 being the predominant genotype 
found. Among the HPV-positive tumors, HPV 16 is the 
most frequent genotype in oropharyngeal HNSCC (86.7%) 
followed by larynx (69.2%) and oral (68.2%). HPV 18 
is the second most frequent genotype detected: 2.8% 
in the oropharynx, 34.1% in the oral cavity and 17% in 
carcinomas of the larynx.
In 2009, the Internationl Agency for Research on 
Cancer evaluated the available evidence on the carcinoge-
nicity of HPV in humans and concluded that there is suffi-
cient evidence for the carcinogenicity of HPV 16 in the oral 
cavity, oropharynx, and tonsils and still limited evidence of 
HPV as a carcinogen in the larynx3. There are significant 
geographical and temporal variations in the incidence of 
HNSCC cancer. Although in Europe and North America, 
non-HPV related HNSCC has been declining, a time-trend 
increase in the incidence of HPV-related oropharyngeal 
cancer has been observed in the last decade9,13-15.
It has been suggested that regional variations in 
global and site-specific incidence of HNSCC seem to relate 
to alcohol and tobacco use and that temporal variations 
may be due to changes in sexual behavior and increased 
exposure to HPV infection16,17. In spite of a very low HPV 
prevalence in HNSCC cases18, Brazil has the highest inci-
dence rate of HNSCC among South American countries1,16. 
Prevention of diseases caused by HPV underlies on the 
introduction of prophylactic vaccines which are highly 
effective in preventing HPV infection19-21. Currently avail-
able vaccines include HPV 16 and 18, the 2 most prevalent 
genotypes in HNSCC. Therefore, it is expected that these 
vaccines have an impact on this type of cancers22.
There are not many studies in South America evalu-
ating the prevalence of HPV in HNSCC. The aim of this 
study was to determine the prevalence of HPV genotypes 
by age and gender in cancer of the oral cavity, oropharynx 
and larynx, in four laboratories of pathology from the city 
of Medellin in Colombia.
METHOD
Study Design and Population
This is a cross-sectional retrospective survey. One 
hundred and seventy-five cases of HNSCC, diagnosed con-
secutively between 1999 and 2008, identified in the records 
of the departments of pathology at the medical and dental 
schools of the University of Antioquia, and in the laboratory 
of pathology and cytology and the department of pathol-
ogy of the University Hospital Fundacion San Vicente de 
Paul were included in the study. The histological slides of 
each case were collected for confirmation of pathological 
diagnosis and the respective paraffin blocks of the con-
firmed cases retrieved for further analysis. Epidemiological 
information on sex, age, year of diagnosis and location 
of the lesion were obtained from the pathology reports.
Microdissection and DNA Extraction
Five histological sections were obtained from each 
paraffin block, wherein the first and the last sections 
stained with hematoxylin & eosin (H & E) were used for 
histological evaluation and the remaining sections for 
microdissection of the lesion. After histological confirma-
tion, lesions were circled and corresponding tumor areas 
microdissected from unstained slides using a sterile surgical 
scalpel in each case. The dissected material was transferred 
to non-silicone tubes and xylene (350 µL) was added to 
each sample to dissolve the paraffin. Paraffin-free tissue 
was precipitated with 150 µL of cold 100% ethanol and 
centrifuged and the pellet was allowed to dry at room 
temperature overnight. Dry button was resuspended in 
100 µL of proteinase K buffer (10 mg/mL proteinase K in 50 
mM Tris, pH 8.3) and incubated overnight at 37°C. Finally 
the samples were incubated at 95°C for 8 min to inactivate 
proteinase K and stored at -20°C until use. Paraffin blocks 
sectioning and DNA extraction was conducted under strict 
conditions to avoid contamination. Blank paraffin blocks 
with normal tissue were included among every 22 samples 
processed, and positive controls were paraffin-embedded 
cervical cancer tissues positive for HPV. DNA quality was 
evaluated by amplifying a 209 bp segment of the human 
β-globin gene.
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HPV DNA detection
Initially, HPV DNA was detected by the HPV general 
primer GP5+/6+ mediated PCR, as described previously23 
and followed by genotyping of PCR products with reverse-
line blot hybridization with specific probes for 37 different 
HPV genotypes (HPV types 6, 11, 16, 18, 26, 31, 33, 34, 35, 
39, 40, 42, 43 , 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 
66, 68, 70, 71, 72, 73, 81, 82/IS39, 82/MM4, 83, 84 , CP6108). 
All samples negative for hybridization after the GP5+/GP6+ 
mediated PCR, were subjected to HPV 16 and HPV 18 
genotype specific PCR as described24. The primers used in 
this procedure amplify a fragment of 96 pb (HPV-16) and 
115 pb (HPV-18) of the E6 gene, which was visualized in 
2% agarose gels stained with ethidium bromide.
Statistical analysis
The cases were described by age, sex and tumor 
location. The percentage of positive cases for any HPV 
genotype, HPV 16 and HPV 18, was estimated among good 
quality samples (β-globin positive or/and HPV positive). A 
descriptive analysis of the frequency of the epidemiological 
characteristics of cases and HPV infection was conducted. 
Subsequently, the risk of HPV infection (for any genotype) 
was estimated by crude or adjusted by age odds ratios, 
with their respective confidence intervals using logistic re-
gression. The nonparametric Mann-Whitney test was used 
to compare differences in age according to HPV status.
These tests were also performed for HPV-16, the 
most common genotype. A significance level of 0.05 was 
used for all analysis and results were generated using the 
statistical package R version 2.12.2 (R Development Core 
Team (2011). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, 
Austria. ISBN 3-900051-07-0, URL. (http://www.R-project.
org/http://www.R-project.org/).
Ethical considerations
The study was approved by the bioethics commit-
tee of the University of Antioquia Research Committee of 
the school of dentistry (Concept 02-2011, May 18, 2011). 
Privacy, confidentiality and anonymity were assured in all 
procedures and the World Medical Association Declaration 
of Helsinki as well as the ethical principles for medical 
research involving human subjects contained in the In-
ternational Ethical Guidelines for Epidemiological Studies 
prepared by the Council for International Organizations of 
Medical Sciences (CIOMS) in collaboration with the World 
Health Organization (WHO) for 2008, were closely followed.
RESULTS
Description of the cases
The characteristics of the 175 cases included in the 
analysis are described in Table 1. Thirty-eight point three 
percent, 36% and 25.7% of lesions were from oral cavity, 
larynx and oropharynx respectively. Age of cases ranged 
from 22 to 97 years and the mean age/(standard devia-
tion) at diagnosis was 64.5/(12.1) years. Overall, there 
was no difference in the mean age/SD at diagnosis among 
lesions from different sites but cases of oral cavity were 
diagnosed at a younger age in men (data not shown). The 
vast majority of cases were between 50 to 79 years old 
and males (63.4%, 111/175). The distribution of cases in 
the oral cavity was similar between males and females. 
However, the percentage of cases from larynx (20.6% vs. 
79.4%) and oropharynx (37.8% vs. 62.2%) was higher in 
males than in females and this was a statistically significant 
difference (Chi-Square test p = 0.0017).
HPV genotyping
Table 2 describes the prevalence of HPV and HPV 
associated factors among the 175 samples. The overall 
prevalence of HPV DNA in HNSCC cases was 18.9%. HPV 
was found in 23.9%, 17.5% and 13.3% of oral cavity, larynx 
and oropharynx cases respectively. Twenty-seven samples 
(15.4%) were positive for HPV 16 and 6 (3.42%) for HPV18. 
Although the mean age of the cases was around 64 years, 
we found a higher prevalence of HPV among younger 
cases. Indeed, the mean age/(SD) of HPV positive cases 
was 60.1/(10.14) years meanwhile the mean age/(SD) of 
the negative cases was 65.5/(12.3) years and this difference 
was statistically significant (Mann-Whitney test p = 0.02).
The proportion of HPV positive HNSCC cases was 
higher in males (22.5%) than in females (12.5%) and the 
probability of HPV positivity of HNSCC cases was two times 
higher in males than females, although this higher probabil-
ity was not statistically significant (OR 2.0, 95% CI: 0.86-4.83) 
and decreased after adjusting for age (OR: 1.53, 95% CI: 
0.61-3.85). Although the proportion of HPV-positive cases 
was higher among cases of oral cavity, than in the cases of 
larynx and oropharynx, these differences were not statisti-
cally significant and remained insignificant after adjustment 
by age. The analysis restricted to cases positive for HPV 
16, also showed that the mean age (60.3/11.4) of positive 
cases was lower than that of negative cases (65.3/12.1), but 
this difference did not reach statistical significance (Mann-
Whitney test p = 0.06). There was not the difference between 
percentages of HPV positive HNSCC cases diagnosed in the 
period 1999-2003 and 2004-2008 (data not shown).
DISCUSSION
The causal association between HPV and a subset 
of HNSCC, has been demonstrated5-7 and studies of case 
series suggest that HPV is associated with a proportion of 
about 25-60% of these cases12. The confirmation of HPV 
association with these cancers opens the opportunity for 
implementing prevention strategies based on the control 
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Table 2. Prevalence and characteristics associated with HPV infection in Head and Neck squamous cell carcinoma cases of 
clinical centers of Medellin, Colombia.
Characteristics
Positivea Negative
OR (95% CI) p ORb (IC 95%) pb
n (%) n (%)
Total 33 (18.9) 142 (81.1) - -
- -
Age, y (Mean/SD) (60.1/10.4) (65.5/12.3) - 0.02c
≤ 39 2 (33.3) 4 (66.7) 1 -
40-49 1 (10.0) 9 (90.0) 0.22 (0.02-3.22)
0.005
50-59 11 (28.2) 28 (71.8) 0.79 (0.13-4.92)
60-69 14 (28.0) 36 (72.0) 0.78 (0.13-4.73)
70-79 4 (8.3) 44 (91.7) 0.18 (0.03-1.32)
≥ 80 0 (0.0) 16 (100) 0.00 -
Missing values 1 - 5 - - -
Gender




Males 25 (22.5) 86 (77.5) 2.03 (0.86-4.83) 1.53 (0.61-3.85)
Anatomic site
Oral cavity 16 (23.9) 51 (76.1) 1
0.350
1
0.153Larynx 11 (17.5) 52 (82.5) 0.67 (0.29-1.59) 0.49 (0.19-1.24)
Oropharynx 6 (13.3) 39 (86.7) 0.49 (0.18-1.37) 0.39 (0.13-1.16)
a 27 HPV 16 and 6 HPV 18 positive; b Adjusted by age; c Mann-Whitney test.




paOral cavity Larynx Oropharynx
n % n % n % n %
Total 175 100.0 67 38.3 63 36 45 25.7 -
Age, y (Mean/SD) (64.5/12.1) (65.9/13.5) (63.5/10.5) (63.9/12.0) 0.396b
≤ 39 6 3.6 4 6.3 1 1.6 1 2.3
0.0524
40-49 10 5.9 2 3.1 5 8.2 3 6.8
50-59 39 23.1 12 18.8 13 21.3 14 31.8
60-69 50 29.6 19 29.7 20 32.8 11 25.0
70-79 48 28.4 16 25.0 22 36.1 10 22.7
≥ 80 16 9.5 11 17.2 0 0.0 5 11.4
Missing information 6 - 3 - 2 - 1 - -
Gender
Female 64 36.6 34 50.7 13 20.6 17 37.8
0.0017
Male 111 63.4 33 49.3 50 79.4 28 62.2
HPV
Negative 142 81.1 51 76.1 52 82.5 39 86.7
0.3530
Positive 33 18.9 16 23.9 11 17.5 6 13.3
a Chi-Square Test; b Kruskal-Wallis test.
of HPV infection. Currently available HPV prophylactic 
vaccines have shown a nearly 100% efficacy in preventing 
infection with HPV 16 and 18, with a projected reduc-
tion in risk of cervical cancer by 50-70% and significant 
impact on non-genital HPV related diseases22. The ability 
of these vaccines to reduce the incidence of these cancers 
may depend partly on the proportion of cases attributed 
to the genotypes included in current available vaccines. 
Estimates of the contribution of HPV genotypes in HNSCC 
are scarce in Latin American countries12.
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In this article we describe the demographic charac-
teristics of 175 cases of HNSCC consecutively diagnosed 
over a period of 10 years (1999-2008) and the prevalence 
of HPV in these cases. Our results show similar preva-
lence of HPV found in other studies conducted in several 
regions worldwide12 but higher than the prevalence de-
scribed in a study including cases from Brazil, Cuba and 
Argentina18. These findings are consistent with observations 
on the geographical variability of the prevalence of HPV 
in HNSCC worldwide. Our study also found that among 
the positive HPV samples, HPV 16 was present in 82% of 
cases, while HPV 18 was observed only in 18% of cases. 
These results are consistent with widely reported data 
which implicates HPV 16 in most cases of HNSCC12,25.
As it has been described26, we also noted that 
despite the high proportion of cases of HNSCC being 
diagnosed in people over 50 years, HPV-positive cases 
tend to be younger than HPV-negative (60.1 vs. 65.5, 
Mann-Whitney test p = 0.02), and this difference persisted 
even when the analysis included only cases positive for 
HPV 16 although this did not reach statistical significance 
(data not shown). The prevalence of HPV in HNSCC in 
this study is higher than that observed in cases from Brazil, 
Argentine and Cuba18. Due to the nature of our study, it 
was not possible to collect information on alcohol and 
tobacco use. It has been suggested that the proportions 
of anatomical sites included in the analysis can influence 
the observed prevalence differences.
The proportion of cancers of the oral cavity, larynx 
and oropharynx in that study was 31%, 49% and 19% 
respectively, which is similar to the proportion of cases 
included in our study. HNSCC is a malignant epithelial 
tumor with squamous differentiation characterized by 
the formation of keratin or the presence of intercellu-
lar bridges or both. Histopathologic characteristics that 
could be evaluated in the study biopsies and resections, 
demonstrated well to moderate differentiated SCC, mostly 
keratinizing tumors, moderate to severe peritumoral in-
flammatory infiltrate and expansive or infiltrative pattern 
of invasion regardless of anatomic sites. HPV has been 
associated as a risk factor for non-keratinizing HNSCC 
occurring in the tonsillar (oropharyngeal and oral) and 
sinunasal areas.
In our study, the proportion of oral cavity HPV-
positive cases was higher than the proportion of larynx and 
oropharynx cases (sinunasal area not included). But these 
differences were not statistically significant and remained 
insignificant after adjustment by age. The lymphoid tissue 
of the tonsillar ring in the head and neck consists of the 
palatine, the pharyngeal and the lingual tonsils, which 
means it is distributed mainly along the oropharynx but 
the oral cavity too. It is worth noting that among the 
evaluated biopsies many were incisional biopsies that 
represent mainly the superficial area of the tumor and did 
not include representation of the non-neoplasic tissues, 
where tonsillar tissue may be recognized more easily.
Even though tonsillar tissue was not observed in 
these oral cavity biopsies, we cannot exclude from the his-
tological slides that in some cases the tumor could involve 
or originated from tonsils and that this could explain the 
higher prevalence of HPV DNA in cases of oral cavity. In 
the same direction, maybe our oropharynx cases did not 
include as many tumors from the tonsils and thus the HPV 
prevalence may have been underestimated. Even further, 
it has been reported that recognition of non-keratinizing 
morphology has low reproducibility27. Another reason 
may be the methods used to determine exposure to HPV. 
For the assessment of prevalence estimates in HNSCC, 
serological tests that detect antibodies against L1 protein, 
E6 and E7 have been used.
Although these essays are useful biomarkers to 
define the role of HPV in HNSCC they may have some 
limitations to estimate the fraction of these cancers at-
tributable to HPV. For example, antibodies against L1 are 
markers of current or previous exposure to HPV infection 
at any anatomical site, including anogenital infections and 
its correlation with the presence of DNA at the site of the 
lesion is very poor28. Antibodies against the E6 and E7 
proteins correlate with invasive cancer at least in cervical 
cancer, but only 60%-70% of HNSCC cases are positive for 
these antibodies29. In cervical cancer, the most accurate 
method in the assessment of the exposure to HPV has 
been PCR of HPV DNA extracted from tumor microdis-
sected lesions30, but the use of paraffin blocks requires the 
implementation of proven methods with high sensitivity 
in paraffin-embedded material.
Although fresh frozen tumor biopsies produce 
good quality DNA, they have the limitation that identi-
fication and microdisection of the tumor tissue cannot 
be conducted. Indeed, strength of our study is the use 
of paraffin blocks, which were re-cut for central pathol-
ogy review and extraction of DNA from the dissected 
material of tumors identified by the study pathologist. 
We also evaluated the quality of DNA by amplifying a 
segment of 209 bp of the β-globin gene and use 2 type 
specific PCR tests that amplify small size fragments (96 
pb for HPV 16 and 115 pb for HPV 18) of the E6 gene 
which have shown to be highly sensitive in this type 
of sample24.
Although we cannot completely exclude the pos-
sibility of false negatives due to technical artifacts, the 
use of highly sensitive type-specific PCR for HPV 16 and 
18 may help to overcome this limitation, especially since 
these two are the predominant genotypes in HNSCC. Po-
tential limitations of our study include possible selection 
bias of samples. The cases were collected from only four 
local laboratories, but we cannot exclude the likelihood 
that these cases do not represent the entire population 
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of cases of HNSCC diagnosed in the geographic area. 
Compared with Brazil, Cuba and Argentina, the incidence 
rate of HNSCC in Colombia is lower31. Likewise, cigarette 
smoking and annual cigarette consumption per person 
is lower in Colombia32,33. It would be useful to evaluate 
HPV prevalence in HNSCC cases in the context of these 
epidemiological profiles to ascertain the fraction attributed 
to each risk factor in HNSCC.
CONCLUSION
The HPV prevalence in these series of cases of four 
laboratories of the city of Medellin, Colombia was 18.9%. 
HPV was found in 23.9%, 17.5% and 13.3% of oral cavity, 
larynx and oropharynx cases respectively. Twenty-seven 
and six samples were HPV 16 (15.4%) and HPV 18 (3.42%) 
respectively. Among HPV positive cases, 82% were HPV 
16 and 18% HPV 18. No other HPV genotypes were 
identified. According to these data, the mass introduction 
of prophylactic HPV vaccines may have the potential to 
reduce the number of HNSCC cases in Colombia, but the 
magnitude of this effect is difficult to predict at this time 
because clinical trials which are specifically designed to 
evaluate the efficacy of these vaccines in the prevention of 
HPV oral infection and on cancers of the head and neck 
have not conducted.
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